Biogen
NEWS
CMS says it would only cover the cost of Biogen’s Aduhelm and any required scans “if they are enrolled in qualifying clinical trials.”
CMS issued a draft decision for Biogen’s Alzheimer’s drug and said it would only cover the cost of Aduhelm and any required scans “if they are enrolled in qualifying clinical trials.”
Bayer isn’t the only company to announce changes to its leadership team this morning. Editas, Biogen, Takeda, Merck and Vedere Bio also announced leadership changes.
This particular renewal panel discussion took an unexpected turn, focusing on Biogen’s controversial drug.
The company indicated that its timeline for an accelerated approval request for its own Alzheimer’s drug, donanemab, was no longer on schedule for the first quarter after the CMS draft guidance.
Alfred Sandrock Jr., the former head of research and development at Biogen, has taken a position on the board of directors of Cambridge, Mass.-based Voyager Therapeutics.
Biogen announced it was exercising its option to participate in Genentech’s development of mosunetuzumab under a long-standing collaboration for antibodies targeting CD20.
One week after Johnna Rossell departed Biogen for Enzyvant, Biogen announced two more members of its board are leaving.
Clinical trial news definitely picked up this final week of January. Here’s a look.
JOBS
IN THE PRESS